Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced that its President and CEO, Steve Griffin, will present at the Canaccord Genuity 2026 Musculoskeletal Conference on March 2, 2026. Management will also hold one-on-one investor meetings at the event. The presentation will be webcast live on Anika's investor relations website.
Anika Therapeutics (ANIK) Expected to Announce Quarterly Earnings on Thursday
Anika Therapeutics (ANIK) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts projecting earnings of $0.02 per share and revenue of $28.875 million. The stock currently trades around $10.52, and institutional investors hold a significant 91.53% of its shares. Analyst consensus rates ANIK as a "Moderate Buy" with a target price of $18.50.
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will issue its fourth quarter and year-end 2025 financial results on Thursday, February 26, 2026, before market open. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights, with access details provided for both dial-in and webcast. The announcement emphasizes Anika's focus on joint preservation in early intervention orthopedics.
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its fourth-quarter and year-end 2025 financial results on Thursday, February 26, 2026, before market open. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
(ANIK) Volatility Zones as Tactical Triggers
This article provides a detailed analysis of Anika Therapeutics Inc. (NASDAQ: ANIK) using AI-generated volatility zones and tactical triggers for trading strategies. It identifies near-term weak sentiment, mid-term strength, and long-term weak bias, offering specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving Average - What's Next?
Anika Therapeutics (NASDAQ:ANIK) stock price has moved above its 200-day moving average of $9.37, trading as high as $10.62. The company has a market cap of $148.97 million, and analyst ratings are mixed but lean towards a "Moderate Buy" with a consensus price target of $18.50. Institutional investors own a significant portion of the company's stock, with hedge funds increasing their positions in the last quarter.
Positive week for Anika Therapeutics, Inc. (NASDAQ:ANIK) institutional investors who lost 41% over the past year
Institutional investors in Anika Therapeutics, Inc. (NASDAQ:ANIK) experienced a positive week with a 17% share price increase, partially recovering from a 41% loss over the past year. Institutions hold a significant 65% ownership, with the top 10 shareholders controlling 51% of the company. BlackRock, Inc. is the largest shareholder at 12%, while insiders own shares valued at US$5.9 million.
Cancer imaging firm Lumicell taps 30-year biotech veteran Cheryl Blanchard for board
Lumicell, a company specializing in fluorescence-guided imaging for cancer detection, has appointed Cheryl R. Blanchard, Ph.D. to its Board of Directors. Dr. Blanchard brings over 30 years of experience in biotech and medtech leadership, including her recent role as President and CEO of Anika Therapeutics, and will remain Executive Chair on Anika's board. Her expertise in commercial and regulatory strategies is expected to significantly aid Lumicell in advancing the adoption of its LumiSystem™ in surgical oncology.
Anika Therapeutics Inc. (NASDAQ:ANIK) Short Interest Update
Anika Therapeutics Inc. (NASDAQ:ANIK) saw a significant increase in short interest in January, with total shorted shares reaching 714,626, a 22.7% rise from December. This represents about 5.5% of the company's shares being shorted. Despite beating recent quarterly EPS estimates, the company remains unprofitable with a negative net margin, and analysts project a full-year EPS of -0.84.
Anika Therapeutics Inc. $ANIK Shares Acquired by Capital Management Corp VA
Capital Management Corp VA significantly increased its stake in Anika Therapeutics Inc. by 34.8% in the third quarter, acquiring an additional 142,403 shares, bringing its total ownership to 551,248 shares valued at approximately $5.18 million. Despite mixed analyst sentiment ranging from "sell" to "buy" with an average price target of $18.50, the biotechnology company posted better-than-expected quarterly EPS of $0.04. Anika Therapeutics specializes in hyaluronic acid-based therapeutic products for orthobiologics and medical devices, with a current market capitalization of $133.10 million.
Price-Driven Insight from (ANIK) for Rule-Based Strategy
Anika Therapeutics Inc. (ANIK) shows weak sentiment across all horizons, supporting a short bias with notable resistance testing. AI models provide distinct trading strategies, including long, breakout, and short positions with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 55.3:1 risk-reward short setup, targeting an 18.0% downside with minimal risk.
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
Kirby McInerney LLP is investigating potential claims on behalf of investors in Anika Therapeutics, Inc. (NASDAQ:ANIK) following a significant decline in share price. This investigation stems from the Company's announcement on July 30, 2025, revealing that its Hyalofast clinical trial did not meet its co-primary endpoints, leading to a 27.42% drop in Anika's stock value. The law firm is seeking to determine if Anika or its management violated federal securities laws or engaged in other unlawful business practices.
United States Joint Pain Injection Market to hit US$ 4.05 Billion
The United States Joint Pain Injection market is projected to reach US$ 4.05 billion by 2033, driven by a growing demand for minimally invasive treatments for osteoarthritis and chronic pain. North America currently holds the largest market share at 35%, with key players like Bioventus, Anika Therapeutics Inc., and Zimmer Biomet leading innovation. The market's growth is also supported by an aging population, increasing musculoskeletal disorders, and advancements in injection therapies such as hyaluronic acid and PRP.
Anika Therapeutics Faces Investor Lawsuit Over Securities Violations
Anika Therapeutics is facing an investor lawsuit from Bragar Eagel & Squire due to alleged federal securities law violations. This comes after the company announced on July 30, 2025, that its Hyalofast product failed to meet primary endpoints in clinical trials, causing a 27.42% stock price drop. The investigation aims to address investor losses caused by poor trial results and missing data.
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is reminding Anika Therapeutics investors about an ongoing investigation into potential federal securities law violations. This follows an announcement by Anika Therapeutics, Inc. that its Hyalofast clinical trial did not meet pre-specified co-primary endpoints, leading to a significant drop in its stock price in July 2025. The firm encourages Anika stockholders who suffered losses to contact them to discuss their legal rights.
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is reminding Anika Therapeutics investors to contact them regarding an ongoing investigation. The investigation stems from Anika's July 2025 announcement of disappointing topline results for its Hyalofast clinical trial, causing a significant drop in the company's stock price. The firm is investigating potential violations of federal securities laws and other unlawful business practices by Anika.
Anika Therapeutics Shares Plunge 27% After Clinical Trial Fails to Meet Primary Endpoints
Anika Therapeutics experienced a 27% share price drop after its Hyalofast clinical trial failed to meet primary endpoints, despite showing improvements in pain and function. This has led to investor concern and an ongoing investigation by Kirby McInerney LLP into potential federal securities law violations by Anika management. While analysts have previously issued positive ratings and price targets for ANIK, the recent clinical trial failure has significantly impacted investor confidence.
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
Kirby McInerney LLP is investigating potential federal securities law violations by Anika Therapeutics, Inc. following a significant stock price drop. This decline occurred after the company announced that its Hyalofast clinical trial did not meet co-primary endpoints, mainly due to a high subject dropout rate and missed visits during COVID-19. Investors who purchased Anika securities are encouraged to contact the firm for more information on the ongoing investigation.
(ANIK) Price Dynamics and Execution-Aware Positioning
This article provides an AI-generated analysis of Anika Therapeutics Inc. (NASDAQ: ANIK) focusing on price dynamics and execution-aware positioning. Key findings suggest stable neutral readings in shorter horizons, potentially easing a long-term weak bias, although no clear price positioning signal is identified with elevated downside risk. The analysis includes institutional trading strategies tailored for different risk profiles, multi-timeframe signal analysis, and real-time AI-generated signals.
Barrington Research Reiterates Outperform Rating for Anika Therapeutics (NASDAQ:ANIK)
Barrington Research has reaffirmed its "Outperform" rating for Anika Therapeutics (NASDAQ:ANIK), setting a price target of $16, which suggests a 67.5% potential upside. Despite slightly exceeding quarterly EPS estimates, the company remains unprofitable, with analysts projecting a negative EPS for the year. Institutional investors hold a significant portion of the stock, and while analyst views are mixed, the consensus remains a "Moderate Buy."
(ANIK) as a Liquidity Pulse for Institutional Tactics
This article from Stock Traders Daily provides an AI-driven analysis of Anika Therapeutics Inc. (NASDAQ: ANIK). It highlights a positive near-term sentiment that may shift, weak broader alignment, and elevated downside risk due to lack of long-term support. The analysis offers specific institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses, based on multi-timeframe signal analysis.
Anika Therapeutics names Stephen Griffin as new CEO
Anika Therapeutics has announced that Stephen Griffin, currently Executive Vice President, CFO, and COO, will become the new President and CEO, effective February 1, 2026. He succeeds Cheryl Blanchard, who will transition to Executive Chair of the Board. The company also reaffirmed its fiscal 2025 guidance and reported a surprising positive EPS for Q3 2025, despite stagnant revenue.
Anika Therapeutics Announces CEO Transition and Governance Changes
Anika Therapeutics announced a leadership transition effective February 1, 2026, with Steve Griffin becoming President and CEO, succeeding Cheryl Blanchard, who will transition to Executive Chair. This multi-year plan also includes governance changes such as a new Lead Independent Director and the resignation of a long-serving director. The company reaffirmed its fiscal 2025 guidance and aims to consolidate leadership to pursue profitable growth in osteoarthritis pain management and regenerative solutions.
Anika Therapeutics Announces Leadership Transition
Anika Therapeutics has announced a leadership transition, appointing Stephen Griffin as its new President and Chief Executive Officer, effective February 1, 2026. Griffin, currently CFO and COO, will succeed Cheryl Blanchard, who will transition to Executive Chair of the Board of Directors. The company also reaffirmed its fiscal 2025 guidance.
Anika Therapeutics Announces Leadership Transition
Anika Therapeutics announced a leadership transition, appointing Stephen Griffin as President and Chief Executive Officer, effective February 1, 2026. He will succeed Cheryl Blanchard, who will become Executive Chair of the Board of Directors. John Henneman, III was named Lead Independent Director, and Susan Vogt's resignation from the Board was accepted.
Anika Therapeutics names Stephen Griffin as new CEO By Investing.com
Anika Therapeutics has announced that Stephen Griffin will become its new President and CEO, effective February 1, 2026, succeeding Cheryl Blanchard who will transition to Executive Chair. Griffin, currently EVP, CFO, and COO, plans to focus on accelerating growth, improving operational discipline, and profitability. The company reaffirmed its fiscal 2025 guidance and specializes in hyaluronic acid products for pain management and regenerative solutions.
Anika Therapeutics Announces Leadership Transition
Anika Therapeutics announced a leadership transition, appointing Stephen (Steve) Griffin as the new President and CEO, effective February 1, 2026. He will succeed Cheryl R. Blanchard, who will become the Executive Chair of the Board of Directors. The company also reaffirmed its fiscal year 2025 guidance.
Anika Therapeutics Announces Leadership Transition
Anika Therapeutics announced a leadership transition, appointing Stephen (Steve) Griffin as President and CEO, effective February 1, 2026. Griffin, previously CFO and COO, succeeds Cheryl Blanchard, who will become Executive Chair of the Board. Additionally, John B. Henneman, III was named Lead Independent Director, and the company reaffirmed its fiscal 2025 guidance.
CFO tapped to lead pain-treatment company as it sticks to 2025 goals
Anika Therapeutics has appointed Stephen (Steve) Griffin as President and CEO, effective February 1, 2026. Griffin, previously the CFO and COO, will succeed Cheryl R. Blanchard, who will become Executive Chair of the Board. The company reaffirmed its fiscal 2025 guidance and highlighted its strategic focus on hyaluronic acid and recent commercial growth.
Anika Therapeutics (NASDAQ: ANIK) names new CEO, reaffirms 2025 outlook
Anika Therapeutics has announced a leadership transition, with Cheryl R. Blanchard stepping down as CEO on February 1, 2026, to become Executive Chair, and Steve Griffin appointed as the new President and CEO. The company also reaffirmed its financial guidance for the year ending December 31, 2025, projecting an Adjusted EBITDA margin between positive 3% and negative 3% of revenue. This leadership change and financial outlook were detailed in a recent SEC Form 8-K filing.
Anika Therapeutics Shares Plunge 27.42% After Clinical Trial Results Fail to Meet Primary Endpoints
Anika Therapeutics experienced a 27.42% share price drop after its Hyalofast clinical trial failed to meet primary endpoints, despite showing improvements in pain and function. The study's data integrity was affected by high dropout rates and missed visits due to COVID, leading to reduced evaluable sample size. As a result, Kirby McInerney LLP has initiated a legal investigation into potential violations of federal securities laws by Anika.
Regenerative Medicine (Bone and Joint) Market Is Going to Boom | Anika Therapeutics, Inc, Arthrex, Inc.
The Regenerative Medicine (Bone and Joint) Market is undergoing significant transformation due to rapid innovation and increasing investment, with strong growth projected from 2025 to 2032. This report provides key insights into market segmentation by type, application, and region, and profiles major companies like Anika Therapeutics and Arthrex, Inc. It offers strategic tools, financial breakdowns, and competitive landscape summaries to help decision-makers capitalize on emerging opportunities in this evolving market.
(ANIK) and the Role of Price-Sensitive Allocations
Anika Therapeutics Inc. (NASDAQ: ANIK) is analyzed, showing stable neutral readings in shorter horizons but an elevated downside risk due to a lack of additional long-term support signals. The article outlines AI-generated institutional trading strategies, including position, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones. Multi-timeframe signal analysis reveals neutral sentiment in near and mid-term horizons and a weak long-term outlook.
Anika Therapeutics’ Earnings Call: Growth Amid Challenges
This article analyzes Anika Therapeutics' latest earnings call, focusing on the company's financial performance and strategic initiatives. It highlights how Anika is navigating market complexities to achieve growth, including key financial metrics and future outlook discussed during the call.
Is the Options Market Predicting a Spike in Anika Therapeutics Stock?
The options market is showing a spike in implied volatility for Anika Therapeutics (ANIK) stock, particularly with the Jun 20, 2025 $10 Call. This suggests investors anticipate a significant price movement. Despite this, analysts currently have a cautious outlook, with the stock holding a Zacks Rank #3 (Hold) and recent downward revisions to earnings estimates.
Responsive Playbooks and the ANIK Inflection
This article analyzes Anika Therapeutics Inc. (NASDAQ: ANIK), identifying weak sentiment across all horizons which supports a short bias. It provides three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also details multi-timeframe signal strengths, support, and resistance levels for ANIK.
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
Kirby McInerney LLP has launched an investigation into Anika Therapeutics, Inc. (NASDAQ: ANIK) concerning potential securities fraud. This follows a significant 27.42% drop in Anika's share price on July 30, 2025, after the company announced its Hyalofast clinical trial did not meet its co-primary endpoints, attributing the outcome to high subject dropout rates and missed visits during COVID. The law firm is seeking investors who purchased Anika securities to discuss their rights and interests.
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP
Kirby McInerney LLP is investigating potential claims against Anika Therapeutics, Inc. (NASDAQ:ANIK) concerning possible violations of federal securities laws. This investigation follows a significant drop in Anika's share price after the company announced its Hyalofast clinical trial did not meet co-primary endpoints, attributing the outcome partly to a high subject dropout rate and missed visits during COVID-19. Investors who purchased Anika securities are encouraged to contact Kirby McInerney LLP to discuss their rights.
Anika Therapeutics (ANIK) Trades Below Fair Value; Valuation Discount Reinforces Cautious Market Narratives
Anika Therapeutics (ANIK) is currently unprofitable but shows revenue growth forecast at 4.7% annually,
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2025 Earnings Call Transcript
Anika Therapeutics (NASDAQ: ANIK) reported a 6% revenue decline in Q3 2025, reaching $27.8 million, missing EPS expectations due to pricing stabilization efforts in its U.S. OA Pain Management business. Despite this, the company saw robust 22% growth in its Commercial Channel, driven by Integrity sales and international OA Pain Management, and maintained its full-year 2025 financial guidance. Anika also made significant progress with regulatory submissions for Hyalofast and Cingal, submitted the third and final PMA module for Hyalofast, and initiated patient screening for the Cingal bioequivalent study.
Anika Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Anika Therapeutics Inc (ANIK) reported an adjusted loss of 16 cents per share for the quarter ended September 30, outperforming analyst expectations of a 27-cent loss. Revenue for the quarter fell 28.2% to $27.82 million. The company's shares have risen 2.4% this quarter but lost 41.5% year-to-date, with analysts maintaining a "strong buy" rating and a median 12-month price target of $15.50.
Earnings call transcript: Anika Therapeutics Q3 2025 sees unexpected EPS rise
Anika Therapeutics Inc. (ANIK) reported an unexpected positive EPS of $0.04 in Q3 2025, significantly beating the forecasted loss of $0.18, leading to a 10.07% premarket stock surge. Despite stagnant revenue at $27.8 million and a 10-percentage-point drop in gross margin, the company maintained its financial guidance for 2025 and reported strong operating cash flow. The company emphasized continued growth in its commercial channel, progress towards FDA approvals for Hyalofast and Cingal, and a second $15 million share repurchase program.
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
Anika Therapeutics has filed the final module of its Premarket Approval (PMA) application for Hyalofast, a cartilage repair scaffold, with the FDA, and announced results from its pivotal Phase III FastTRACK clinical trial. While the study did not meet its pre-specified co-primary endpoints under the original statistical framework, post-hoc analyses and secondary endpoints showed statistically significant improvements and clinically meaningful benefits compared to microfracture. Anika remains confident in Hyalofast's clinical value, citing real-world experience and Breakthrough Device Designation.
Anika Therapeutics Inc (NASDAQ:ANIK) Reports Q3 2025 Earnings Beat and Positive Regulatory Milestone
Anika Therapeutics Inc (NASDAQ:ANIK) reported a significant Q3 2025 earnings beat with a profit of $0.04 per share, despite slightly missing revenue expectations at $27.82 million. The company also announced strong commercial growth, with a 22% year-over-year increase in commercial channel revenue, and a key regulatory milestone, having filed the third and final module of its PMA application for the Hyalofast cartilage repair scaffold with the FDA. Shares reacted positively, rising over 10% in pre-market trading.
Anika Reports Third Quarter 2025 Financial Results
Anika Therapeutics, Inc. reported its third-quarter 2025 financial results, highlighting a 22% increase in Commercial Channel revenue driven by strong performance from its Integrity Implant System and Hyalofast products. Despite an overall 6% revenue decrease due to a planned 20% decline in OEM Channel revenue, the company reaffirmed its fiscal 2025 guidance and announced a $15 million share repurchase program. Key milestones include the Hyalofast PMA submission and Cingal surpassing one million injections worldwide.
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
Anika Therapeutics has filed the third and final module of its Premarket Approval application (PMA) for Hyalofast, a hyaluronic acid-based scaffold for treating articular cartilage defects in the knee. The company also announced results from its pivotal Phase III FastTRACK clinical trial. Although the study did not meet its pre-specified co-primary endpoints under the original statistical framework, secondary endpoint and post-hoc analyses showed statistically significant improvements and clinically meaningful benefits with Hyalofast.
Anika Therapeutics, Inc. (NASDAQ:ANIK) is a favorite amongst institutional investors who own 60%
Institutional investors own 60% of Anika Therapeutics, Inc. (NASDAQ:ANIK), indicating significant influence over the company's share price and expressing confidence in its future. The top 8 shareholders collectively own 51% of the company, with hedge funds specifically holding 24% and aiming for short-to-medium term value creation. Insiders also hold a stake of US$5.8 million, while the general public owns 12% of the company.
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025
Anika Therapeutics, Inc. announced plans to issue its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the live audio webcast and presentation materials via the Investor Relations section of Anika's website.
Anika Therapeutics Shares Face Mounting Pressure Amid Technical and Legal Woes - AD HOC NEWS
Anika Therapeutics is experiencing a significant downward trend in its equity value due to a substantial price decline, subdued trading activity, and negative investor sentiment. This decline is attributed to bearish technical indicators, ongoing legal probes, and a key setback during a clinical trial for a cartilage repair product. Despite surpassing revenue projections for Q2 2025 and subsequent equity inductions, the company faces mounting pressure.
Viscosupplementation Market Size & Share, Forecast, 2032
The viscosupplementation market, valued at USD 2.75 billion in 2023, is projected to grow to USD 4.60 billion by 2032 with a CAGR of 5.9%, driven by the rising prevalence of osteoarthritis and increased demand for non-surgical treatments. North America currently dominates the market, with key players focusing on mergers, acquisitions, and product development. The market faces challenges due to the high cost of therapy.
